van Rijt, Sabine H., Kostrhunova, Hana, Brabec, V. (Viktor) and Sadler, P. J.. (2011) Functionalization of osmium arene anticancer complexes with (poly)arginine : effect on cellular uptake, internalization, and cytotoxicity. Bioconjugate Chemistry, Vol.22 (No.2). pp. 218-226. ISSN 1043-1802

Preview

Text WRAP_vanRijt_459_bc-2010-00369pScript_RevFinal3.pdf - Accepted Version Download (1199Kb) | Preview

Abstract

Attaching peptides to metallodrugs may result in improved biological properties of the complexes. The potential use of cell penetrating peptides (CPPs) as cell delivery vectors is attractive, since directed cell uptake of (metallo)drugs remains a major challenge in anticancer drug design. In this work, we report the synthesis of peptide conjugates of the organometallic OsII anticancer complex [(η6-biphenyl)Os(picolinate)Cl] with different arginine (Arg) chain lengths. Complexes conjugated to Arg5 or Arg8 at the 5-position of the picoline ring increase Os uptake into A2780 human ovarian cancer cells by ca. 2× and 10×, respectively, whereas a single Arg had no effect. Furthermore, a 15-fold increase in binding of Os to DNA, a potential target for these complexes, was observed for Arg8 compared to the Arg1 conjugate. The Arg5 and Arg8 conjugates exhibited fast kinetics of binding to calf thymus DNA and an ability to precipitate DNA at very low concentrations. In serum-free medium, the Arg8 complex was cytotoxic (IC50 33 μM) and appears to be a rare example of a bioactive organometallic peptide conjugate. Experiments on CHO cells deficient in DNA repair suggested that unrepaired DNA damage contributes to the cytotoxicity of the Arg5 and Arg8 conjugates. These studies demonstrate the potential for use of cell- and nucleus-penetrating peptides in targeting organometallic arene anticancer complexes.

Item Type:	Journal Article
Subjects:	Q Science > QD Chemistry R Medicine > RC Internal medicine > RC0254 Neoplasms. Tumors. Oncology (including Cancer) R Medicine > RS Pharmacy and materia medica
Divisions:	Faculty of Science > Chemistry
Library of Congress Subject Headings (LCSH):	Antineoplastic agents -- Design, Osmium, Arginine, Organometallic compounds, Peptide drugs, Peptides -- Synthesis, Cell-mediated cytotoxicity
Journal or Publication Title:	Bioconjugate Chemistry
Publisher:	American Chemical Society
ISSN:	1043-1802
Date:	2011
Volume:	Vol.22
Number:	No.2
Page Range:	pp. 218-226
Identification Number:	10.1021/bc100369p
Status:	Peer Reviewed
Publication Status:	Published
Access rights to Published version:	Restricted or Subscription Access
Funder:	Engineering and Physical Sciences Research Council (EPSRC), European Research Council (ERC), European Regional Development Fund (ERDF), Advantage West Midlands (AWM), Czech Science Foundation (CSF), Akademie věd České republiky [Academy of Sciences of the Czech Republic] (ASCR)
Grant number:	EP/H500308/1 (EPSRC), 247450 (ERC), P301/10/0598 (CSF), M200040901 (ASCR)
References:	(1) Vivès, E., (2005) Present and future of cell-penetrating peptide mediated delivery systems: "is the Trojan horse too wild to go only to Troy?". J. Control Release 109, 77-85. (2) Vivès, E., Schmidt, J., Pèlegrin, A., (2008) Cell-penetrating and cell-targeting peptides in drug delivery. Biochim. Biophys. Acta 1786, 126-138. (3) Futaki, S., (2002) Arginine-rich peptides: potential for intracellular delivery of macromolecules and the mystery of the translocation mechanisms. Int. J. Pharm. 245, 1-7. (4) Magzoub, M. and Graslund, A., (2004) Cell-penetrating peptides: from inception to application. Q. Rev. Biophys. 37, 147-195. (5) Wright, L. R., Rothbard, J. B., Wender, P. A., (2003) Guanidinium rich peptide transporters and drug delivery. Curr. Protein Pept. Sci. 4, 105-124. (6) Mitchell, D. J., Kim, D. T., Steinman, L., Fathman, C. G., and Rothbard, J. B., (2000) Polyarginine enters cells more efficiently than other polycationic homopolymers. J. Pept. Res. 56, 318-325. (7) Wender, P. A., Mitchell, D. J., Steinman, L., Fathman, C. G., and Rothbard, J. B., (2000) The design, synthesis, and evaluation of molecules that enable or enhance cellular uptake: peptoid molecular transporters. Proc. Natl. Acad. Sci. U S A, 97, 13003-13008. (8) Dyson, P. J. and Sava, G., (2006) Metal-based antitumour drugs in the post genomic era. Dalton Trans. 1929-1933. (9) Melchart, M., Habtemariam, A., Parsons, S., Moggach, S. A., and Sadler, P. J., (2006) Ruthenium(II) arene complexes containing four- and five-membered monoanionic O,O-chelate rings. Inorg. Chim. Acta, 359, 3020-3028. (10) Berners-Price, S. J. and Filipovska, A., (2008) The design of gold-based, mitochondria-targeted chemotherapeutics. Aust. J. Chem. 61, 661-668. (11) Jakupec, M. A., Galanski, M., Arion, V. B., Hartinger, C. G., and Keppler, B. K., (2008) Antitumour metal compounds: more than theme and variations. Dalton Trans. 183-194. (12) Brunner, J. and Barton, J. K., (2006) Targeting DNA mismatches with rhodium intercalators functionalized with a cell-penetrating peptide. Biochemistry, 45, 12295-12302. (13) Noor, F., Wustholz, A., Kinscherf, R, and Metzler-Nolte, N., (2005) A cobaltocenium-peptide bioconjugate shows enhanced cellular uptake and directed nuclear delivery. Angew. Chem. Int. Ed. Engl. 44, 2429-2432. (14) Cebrian-Losantos, B., Krokhin, A. A., Stepanenko, I. N., Eichinger R., Jakupec, M. A., Arion, V. B., and Keppler, B. K., (2007) Osmium NAMI-A analogues: Synthesis, structural and spectroscopic characterization, and antiproliferative properties. Inorg. Chem. 46, 5023-5033. (15) Peacock, A. F. A., Parsons, S., and Sadler, P. J., (2007) Tuning the hydrolytic aqueous chemistry of osmium arene complexes with N,O-chelating ligands to achieve cancer cell cytotoxicity. J. Am. Chem. Soc. 129, 3348-3357. (16) Maksimoska, J., Williams, D. S., Atilla-Gokcumen, G. E., Smalley, K. S., Carroll, P. J., Webster, R. D., Filippakopoulos, P., Knapp, S., Herlyn, M., and Meggers, E., (2008) Similar biological activities of two isostructural ruthenium and osmium complexes. Chem-Eur. J. 14, 4816-4822. (17) Renfrew, A. K., Phillips, A. D., Egger, A. E., Hartinger, C. G., Bosquain, S. S., Nazarov, A. A., Keppler, B. K., Gonsalvi, L., Peruzzini, M., and Dyson, P. J., (2009) Influence of Structural Variation on the Anticancer Activity of RAPTA-Type Complexes: ptn versus pta. Organometallics 28, 1165-1172. (18) van Rijt, S. H., Hebden, A. J., Amaresekera T., Deeth R. J., Clarkson G. J., Parsons S., McGowan P. C., and Sadler, P. J., (2009) Amide Linkage Isomerism As an Activity Switch for Organometallic Osmium and Ruthenium Anticancer Complexes. J. Med. Chem. 52, 7753-7764. (19) van Rijt, S. H., Peacock, A. F. A., Johnstone, R. D., Parsons, S., and Sadler, P. J., (2009) Organometallic Osmium(II) Arene Anticancer Complexes Containing Picolinate Derivatives. Inorg. Chem. 48, 1753-1762. (20) Barry, N. P. E., Edafe, F., Dyson, P. J., and Therrien, B., (2010) Anticancer activity of osmium metalla-rectangles. Dalton Trans. 39, 2816-2820. (21) Hanif, M., Nazarov, A. A., Hartinger, C. G., Kandioller, W., Jakupec, M. A., Arion, V. B., Dyson, P. J., and Keppler, B. K., (2010) Osmium(II)-versus ruthenium(II)-arene carbohydrate-based anticancer compounds: similarities and differences. Dalton Trans. 39, 7345-7352. (22) Kostrhunova, H., Florian, J., Novakova, O., Peacock, A. F., Sadler P. J., and Brabec V., (2008) DNA interactions of monofunctional organometallic osmium(II) antitumor complexes in cell-free media. J. Med. Chem. 51, 3635-3643. (23) Brabec, V. and Palecek, E., (1970) The influence of salts and pH on polarographic currents produced by denatured DNA. Biophysik, 6, 290-300. (24) Brabec, V. and Palecek, E., (1976) Interaction of nucleic acids with electrically charged surfaces. II. Conformational changes in double-helical polynucleotides. Biophys. Chem. 4, 79-92. (25) Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., and Boyd, M. R., (1990) New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 82, 1107-1112. (26) Hall, H., Gursky, J., Nicodemou, A., Rybanská, .I., Kimlíčková, E., and Piršel, M., (2006) Characterization of ERCC3 mutations in the Chinese hamster ovary 27-1, UV24 and MMC-2 cell lines. Mutat. Res-Fund. Mol. M., 593, 177-186. (27) van Rijt, S. H., Mukherjee, A., Pizarro, A. M., and Sadler, P. J., (2010) Cytotoxicity, Hydrophobicity, Uptake, and Distribution of Osmium(II) Anticancer Complexes in Ovarian Cancer Cells. J. Med. Chem. 53, 840-849. (28) Gammon, S. T., Villalobos, V. M., Prior, J. L., Sharma, V., and Piwnica-Worms, D., (2003) Quantitative analysis of permeation peptide complexes labeled with Technetium-99m: chiral and sequence-specific effects on net cell uptake. Bioconjug. Chem. 14, 368-376. (29) Youngblood, D. S., Hatlevig, S. A., Hassinger, J. N., Iversen, P. L., and Moulton, H. M., (2007) Stability of cell-penetrating peptide-morpholino oligomer conjugates in human serum and in cells. Bioconjug. Chem. 18, 50-60. (30) Metzler-Nolte, N., (2001) Labeling of Biomolecules for Medicinal Applications-Bioorganometallic Chemistry at Its Best. Angew. Chem. Int. Ed. Engl. 40, 1040-1043. (31) Splith, K., Neundorf, I., Peindy N'Dongo, H. W., Vasylyeva, V., Merz, K., and Schatzschneider, U., (2010) Influence of the metal complex-to-peptide linker on the synthesis and properties of bioactive CpMn(CO)3 peptide conjugates. Dalton Trans. 39, 2536-2545. (32) Bertucci, C. and Domenici, E., (2002) Reversible and covalent binding of drugs to human serum albumin: methodological approaches and physiological relevance. Curr. Med. Chem. 9, 1463-1481. (33) Dietz, G. P. H. and Bahr, M., (2004) Delivery of bioactive molecules into the cell: The Trojan horse approach. Mol. Cell Neurosci. 27, 85-131. (34) Johnson, N. P., Butour, J. L., Villani, G., Wimmer, F. L., Defais, M., Pierson, V., and Brabec, V., (1989) Metal antitumor compounds: The mechanism of action of platinum complexes. Prog. Clin. Biochem. Med. 10, 1-24.
URI:	http://wrap.warwick.ac.uk/id/eprint/37092

Data sourced from Thomson Reuters' Web of Knowledge

Request changes to a record

Actions (login required)

View Item